CIK 0001125345
- Non-accelerated filer
- Smaller reporting company
MACROGENICS INC
Sign in to watch- Ticker
- MGNX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 301-251-5172
- Business address
- 9704 MEDICAL CENTER DRIVE, Rockville, MD, 20850
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-16 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Exercise or conversion | +2,476 | $4.70 | $12K | 32,476 |
| 2018-01-16 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Sale | −2,476 | $20.00 | $50K | 30,000 |
| 2018-01-16 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Exercise or conversion · Employee stock option (right to buy) | −2,476 | 47,972 | ||
| 2017-12-29 | Karrels James SVP, CFO and Secretary | Exercise or conversion | +3,000 | $0.94 | $3K | 113,331 |
| 2017-12-29 | Karrels James SVP, CFO and Secretary | Exercise or conversion · Employee stock option (right to buy) | −3,000 | 6,516 | ||
| 2017-11-21 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Exercise or conversion | +5,000 | $4.70 | $24K | 35,000 |
| 2017-11-21 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Sale | −5,000 | $20.00 | $100K | 30,000 |
| 2017-11-21 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Exercise or conversion · Employee stock option (right to buy) | −5,000 | 50,448 | ||
| 2017-11-13 | SIEGEL JAY PHILIP Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2017-10-25 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Exercise or conversion | +10,000 | $4.70 | $47K | 40,000 |
| 2017-10-25 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Sale | −10,000 | $20.00 | $200K | 30,000 |
| 2017-10-25 | Wigginton Jon Marc Sr VP, Clinical Dev. & CMO | Exercise or conversion · Employee stock option (right to buy) | −10,000 | $4.70 | $47K | 55,448 |
| 2017-09-05 | Karrels James SVP, CFO and Secretary | Exercise or conversion | +5,000 | $0.94 | $5K | 110,331 |
| 2017-09-05 | Karrels James SVP, CFO and Secretary | Exercise or conversion · Employee stock option (right to buy) | −5,000 | 9,516 | ||
| 2017-09-05 | Risser Eric Blasius Sr VP & Chief Business Officer | Exercise or conversion | +2,000 | $0.94 | $2K | 6,000 |
| 2017-09-05 | Risser Eric Blasius Sr VP & Chief Business Officer | Exercise or conversion · Employee stock option (right to buy) | −2,000 | 31,497 | ||
| 2017-07-26 | Bonvini Ezio Sr VP, Research & CSO | Exercise or conversion | +26,632 | $1.51 | $40K | 120,026 |
| 2017-07-26 | Bonvini Ezio Sr VP, Research & CSO | Exercise or conversion | +26,632 | $0.94 | $25K | 146,658 |
| 2017-07-26 | Bonvini Ezio Sr VP, Research & CSO | Exercise or conversion · Employee stock option (right to buy) | −26,632 | $1.51 | $40K | 0 |
| 2017-07-26 | Bonvini Ezio Sr VP, Research & CSO | Exercise or conversion · Employee stock option (right to buy) | −26,632 | $0.94 | $25K | 0 |
Page 34 of 35 · 684 trades